Press Releases

ST. PAUL, Minn., Nov. 20, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today it has entered into a definitive agreement to acquire Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care for $725 million in cash plus up to $125 million in contingent cash payments based on the achievement of certain future milestones.

ST. LOUIS, June 25, 2025 /PRNewswire/ -- Acera Surgical, a pioneer in synthetic Electrospun materials for soft tissue repair, today announced it has received an additional U.S. Food and Drug Administration (FDA) 510(k) clearance for Restrata®, a fully synthetic, fully resorbable electrospun matrix. This new clearance broadens the clinical utility of the Restrata platform, now supporting soft tissue reinforcement applications in addition to its previously cleared indications for wound healing. This clearance applies to both Restrata Sheet and Restrata Meshed products.

ST. LOUIS, May 11, 2022 /PRNewswire/ -- Acera Surgical, Inc. (Acera), a leading bioscience company developing and commercializing a portfolio of fully synthetic materials for regenerative medical applications, today announced that Michael Finegan is joining the company as CEO, effective immediately.
News Stories

In a recent CBS Austin news segment, Dr. Sudeep Burman of ATX Robotic Surgery shared the remarkable recovery story of Texas rancher John Moore, who suffered a devastating soft tissue injury after being kicked by a cow. After debridement, Dr. Burman applied Restrata MiniMatrix, the first FDA-cleared synthetic electrospun fiber matrix for soft tissue repair. Restrata mimics the bodies own extracellular matrix, encouraging healing and helping patients like John return to what they love most.